Arena Pharmaceuticals’ Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
SAN DIEGO, Oct. 9, 2020 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from the Phase 2 OASIS trial and its open-label extension for its investigative drug candidate etrasimod, a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderately to severely active ulcerative colitis (UC) at the 26th Annual United European Gastroenterology (UEG) Week. Arena will also present preclinical data for olorinab, a peripherally acting, highly selective, full agonist of the cannabinoid receptor 2 (CB2), in development for the treatment of visceral pain in gastrointestinal (GI) diseases. UEG Week is taking place virtually October 11-13, 2020.
Arena Sponsored Symposium Details:
Title: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us?
Intended Audience: This symposium is designed for non-US healthcare professionals and is not affiliated with UEGW
Speakers: William Sandborn, MD (Chair), Professor Silvio Danese, Remo Panaccione, MD, FRCPC
Day/Time: Monday, October 12 at 17:30 CET
Presentation Details:
Title: Early and Durable Symptom Control in Patients with Moderately to Severely Active Ulcerative Colitis Treated with Etrasimod in the Randomised, Double Blind, Placebo Controlled, Phase 2 OASIS Trial and Open Label Extension
Day/Time: Tuesday, October 13, 2020, from 15:00-16:00 CET
ePoster: P0481
Title: Expression of Cannabinoid Receptors and the Effect of Olorinab, a Peripherally Acting, Highly Selective, Full Agonist of the Cannabinoid Receptor 2, on Visceral Hypersensitivity in Rodent Models of Irritable Bowel Syndrome and Inflammatory Bowel Disease
Day/Time: Sunday, October 11, 2020, 18:00-19:00 CET
Oral presentation: OP058
Title: The Incremental Increasing Rate of Thromboembolic Events in Patients with Inflammatory Bowel Disease Compared to Patients Without Autoimmune Disorder
Event: Virtual poster exhibition
ePoster: P0377
About Etrasimod
Etrasimod (APD334) is a once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator, discovered by Arena, designed